Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow Jrheum on BlueSky
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
Research ArticleSystemic Sclerosis

Worldwide Expert Agreement on Updated Recommendations for the Treatment of Systemic Sclerosis

Jeska K. de Vries-Bouwstra, Yannick Allanore, Marco Matucci-Cerinic and Alexandra Balbir-Gurman
The Journal of Rheumatology February 2020, 47 (2) 249-254; DOI: https://doi.org/10.3899/jrheum.181173
Jeska K. de Vries-Bouwstra
From Leiden University Medical Center, Department of Rheumatology, Leiden, the Netherlands; Paris Descartes University, Cochin Hospital, Rheumatology Department, Paris, France; Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy; B. Shine Rheumatology Unit, Rambam Health Care Campus, Rappaport Faculty of Medicine, Technion, Haifa, Israel.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jeska K. de Vries-Bouwstra
  • For correspondence: j.k.de_vries-bouwstra@lumc.nl
Yannick Allanore
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marco Matucci-Cerinic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexandra Balbir-Gurman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • References
  • PDF
PreviousNext
Loading

REFERENCES

  1. 1.↵
    1. Taba P,
    2. Rosenthal M,
    3. Habicht J,
    4. Tarien H,
    5. Mathiesen M,
    6. Hill S,
    7. et al.
    Barriers and facilitators to the implementation of clinical practice guidelines: a cross-sectional survey among physicians in Estonia. BMC Health Serv Res 2012;12:455.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Volkmann ER,
    2. Chung A,
    3. Tashkin DP
    . Managing systemic sclerosis-related interstitial lung disease in the modern treatment era. J Scleroderma Relat Disord 2017;2:72–83.
    OpenUrl
  3. 3.↵
    1. Kowal-Bielecka O,
    2. Fransen J,
    3. Avouac J,
    4. Becker M,
    5. Kulak A,
    6. Allanore Y,
    7. et al;
    8. EUSTAR Coauthors
    . Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis 2017;76:1327–39.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Kowal-Bielecka O,
    2. Landewe R,
    3. Avouac J,
    4. Chwiesko S,
    5. Miniati I,
    6. Czirjak L,
    7. et al;
    8. EUSTAR Co-Authors
    . EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 2009;68:620–8.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Pellar RE,
    2. Pope JE
    . Evidence-based management of systemic sclerosis: navigating recommendations and guidelines. Sem Arthritis Rheum 2017;46:767–74.
    OpenUrl
  6. 6.↵
    1. Muller-Ladner U,
    2. Tyndall A,
    3. Czirjak L,
    4. Denton C,
    5. Matucci-Cerinic M
    . Ten years EULAR Scleroderma Research and Trials (EUSTAR): what has been achieved? Ann Rheum Dis 2014;73:324–7.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Proudman SM,
    2. Stevens W,
    3. Wilson ME,
    4. Sahhar J,
    5. Hudson M,
    6. Pope J,
    7. et al.
    What have multicentre registries across the world taught us about the disease features of systemic sclerosis? J Scleroderma Relat Disord 2017;2:169–82.
    OpenUrl
  8. 8.↵
    1. Birrenbach T,
    2. Kraehenmann S,
    3. Perrig M,
    4. Berendonk C,
    5. Huwendiek S
    . Physicians’ attitudes toward, use of, and perceived barriers to clinical guidelines: a survey among Swiss physicians. Adv Med Educ Pract 2016;7:673–80.
    OpenUrl
  9. 9.↵
    1. Cabana MD,
    2. Rand CS,
    3. Powe NR,
    4. Wu AW,
    5. Wilson MH,
    6. Abboud PA,
    7. et al.
    Why don’t physicians follow clinical practice guidelines? A framework for improvement. JAMA 1999;282:1458–65.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Walker KM,
    2. Pope J;
    3. Scleroderma Clinical Trials Consortium;
    4. Canadian Scleroderma Research Group
    . Expert agreement on EULAR/EUSTAR recommendations for the management of systemic sclerosis. J Rheumatol 2011;38:1326–8.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Vidal C,
    2. Ruano C,
    3. Bernardino V,
    4. Lavado P,
    5. Lladó A,
    6. Santos M,
    7. et al.
    EUSTAR registration impacts favourably on clinical practice. J Scleroderma Relat Disord 2017;2:e4.
    OpenUrl
  12. 12.↵
    1. Ingegnoli F,
    2. Schioppo T,
    3. Allanore Y,
    4. Caporali R,
    5. Colaci M,
    6. Distler O,
    7. et al.
    Practical suggestions on intravenous iloprost in Raynaud’s phenomenon and digital ulcer secondary to systemic sclerosis: systematic literature review and expert consensus. Sem Arthritis Rheum 2019;48:686–93.
    OpenUrl
  13. 13.↵
    1. Guyatt G,
    2. Oxman AD,
    3. Akl EA,
    4. Kunz R,
    5. Vist G,
    6. Brozek J,
    7. et al.
    GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 2011;64:383–94.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Coleiro B,
    2. Marshall SE,
    3. Denton CP,
    4. Howell K,
    5. Blann A,
    6. Welsh KI,
    7. et al.
    Treatment of Raynaud’s phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology 2001;40:1038–43.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Spierings J,
    2. van Rhijn-Brouwer FCC,
    3. van Laar JM
    . Hematopoietic stem-cell transplantation in systemic sclerosis: an update. Curr Opin Rheumatol 2018;30:541–7.
    OpenUrl
  16. 16.↵
    1. Denoeud L,
    2. Mazieres B,
    3. Payen-Champenois C,
    4. Ravaud P
    . First line treatment of knee osteoarthritis in outpatients in France: adherence to the EULAR 2000 recommendations and factors influencing adherence. Ann Rheum Dis 2005;64:70–4.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    1. Herrick AL
    . Controversies on the use of steroids in systemic sclerosis. J Scleroderma Relat Disord 2017;2:84–91.
    OpenUrl
  18. 18.↵
    1. Herrick AL,
    2. Gallas A
    . Systemic sclerosis-related calcinosis. J Scleroderma Relat Disord 2016;1:194–203.
    OpenUrl
  19. 19.↵
    1. Khanna D,
    2. Distler JH,
    3. Sandner P,
    4. Distler O
    . Emerging strategies for treatment of systemic sclerosis. J Scleroderma Relat Disord 2016;1:186–93.
    OpenUrl
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 47, Issue 2
1 Feb 2020
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Worldwide Expert Agreement on Updated Recommendations for the Treatment of Systemic Sclerosis
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Worldwide Expert Agreement on Updated Recommendations for the Treatment of Systemic Sclerosis
Jeska K. de Vries-Bouwstra, Yannick Allanore, Marco Matucci-Cerinic, Alexandra Balbir-Gurman
The Journal of Rheumatology Feb 2020, 47 (2) 249-254; DOI: 10.3899/jrheum.181173

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Worldwide Expert Agreement on Updated Recommendations for the Treatment of Systemic Sclerosis
Jeska K. de Vries-Bouwstra, Yannick Allanore, Marco Matucci-Cerinic, Alexandra Balbir-Gurman
The Journal of Rheumatology Feb 2020, 47 (2) 249-254; DOI: 10.3899/jrheum.181173
del.icio.us logo Twitter logo Facebook logo  logo Mendeley logo
  • Tweet Widget
  •  logo
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • ONLINE SUPPLEMENT
    • Acknowledgment
    • REFERENCES
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • References
  • PDF

Keywords

SYSTEMIC SCLEROSIS
DRUG THERAPY
PRACTICE GUIDELINES
GUIDELINE ADHERENCE

Related Articles

Cited By...

More in this TOC Section

  • Improving Systemic Sclerosis Quality of Care
  • Pulmonary Arterial Hypertension Incidence in Patients With Systemic Sclerosis Treated With Bosentan for Digital Ulcers: Evidence From the SPRING-SIR Registry
  • Psychometric Evaluation of the Scleroderma Skin Questionnaire: A Novel Patient-Reported Outcome for Skin Disease in Patients With Systemic Sclerosis
Show more Systemic Sclerosis

Similar Articles

Keywords

  • systemic sclerosis
  • DRUG THERAPY
  • practice guidelines
  • GUIDELINE ADHERENCE

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2025 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire